A PHASE 3, PROSPECTIVE, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF IGPRO20 IN SUBJECTS WITH SECONDARY IMMUNE DEFICIENCY DUE TO HEMATOLOGIC MALIGNANCIES TREATED WITH B-CELL TARGETING CHIMERIC ANTIGEN RECEPTOR T-CELL REDIRECTING THERAPIES

Registry ID

IGPRO20_3013

Source registry

HEALTH_CANADA

Status

Pending

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

CSL BEHRING

Last update

2026-07-15

Conditions

• SECONDARY IMMUNODEFICIENCY DISEASES
• HEMATOLOGICAL MALIGNANCIES

Related clinical trials

• LIGHTBEAM-U01 SUBSTUDY 01A: A PHASE 1/2 SUBSTUDY TO EVALUATE THE SAFETY AND EFFICACY OF ZILOVERTAMAB VEDOTIN IN PEDIATRIC AND YOUNG ADULT PARTICIPANTS WITH HEMATOLOGIC MALIGNANCIES OR SOLID TUMORS
• PHASE IB OPEN LABEL BASKET TRIAL OF RAY121 TO INHIBIT CLASSICAL COMPLEMENT PATHWAY IN IMMUNOLOGICAL DISEASES (RAINBOW TRIAL)
• AN OPEN-LABEL, MULTICENTER, ROLL-OVER STUDY FOR PATIENTS WHO HAVE COMPLETED A PRIOR NOVARTIS-SPONSORED SABATOLIMAB (MBG453) STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT WITH SABATOLIMAB
• PHASE 1/2 STUDY OF 9-ING-41, A GLYCOGEN SYNTHASE KINASE-3 BETA (GSK-3B) INHIBITOR, AS A SINGLE AGENT AND COMBINED WITH CHEMOTHERAPY, IN PATIENTS WITH REFRACTORY HEMATOLOGIC MALIGNANCIES OR SOLID TUMORS
• A PHASE 2, OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK- 7684A (MK-7684 [VIBOSTOLIMAB] WITH MK-3475 [PEMBROLIZUMAB] COFORMULATION) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY HEMATOLOGICAL MALIGNANCIES
• A PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MK-1026 IN PARTICIPANTS WITH HEMATOLOGIC MALIGNANCIES

View on source registry